Beam Therapeutics Inc. (BEAM) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BEAM Revenue Growth
BEAM Revenue Analysis (2017–2025)
As of May 8, 2026, Beam Therapeutics Inc. (BEAM) generated trailing twelve-month (TTM) revenue of $132.3 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, BEAM's 5-year compound annual growth rate (CAGR) stands at +466.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $377.7 million in 2023.
When compared to Healthcare sector peers including CRSP (-88.9% YoY), NTLA (+16.9% YoY), and PRME (-17.4% YoY), BEAM has underperformed the peer group in terms of revenue growth. Compare BEAM vs CRSP →
BEAM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BEAMCurrent | $132M | -100.0% | +466.3% | -274.6% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 PRME | $5M | -17.4% | -2.3% | -4498.1% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% |
BEAM Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $139.7M | +120.0% | $117.4M | 84.0% | $-383,693,000 | -274.6% |
| 2024 | $63.5M | -83.2% | $-304,043,000 | -478.7% | $-415,568,000 | -654.3% |
| 2023 | $377.7M | +520.0% | $377.7M | 100.0% | $-176,485,000 | -46.7% |
| 2022 | $60.9M | +17.5% | $-250,674,000 | -411.5% | $-338,479,000 | -555.6% |
| 2021 | $51.8M | +215916.7% | $-180,290,000 | -347.8% | $-392,465,000 | -757.0% |
| 2020 | $24K | +33.3% | $-103,155,000 | -429812.5% | $-132,759,999 | -553166.7% |
| 2019 | $18K | - | $-54,601,000 | -303338.9% | $-75,154,000 | -417522.2% |
| 2018 | $0 | - | $-33,873,000 | - | $-45,741,000 | - |
| 2017 | $0 | - | $0 | - | $-8,596,363 | - |
See BEAM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BEAM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BEAM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBEAM — Frequently Asked Questions
Quick answers to the most common questions about buying BEAM stock.
Is BEAM's revenue growth accelerating or slowing?
BEAM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +466.3%. TTM revenue fell to $132M. This reverses the prior growth trend.
What is BEAM's long-term revenue growth rate?
Beam Therapeutics Inc.'s 5-year revenue CAGR of +466.3% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is BEAM's revenue distributed by segment?
BEAM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.